Consent given pursuant to sections 14 and 14A for the supply and importation of the Therapeutic Goods specified subject to conditions specified - between 29 July 2014 and 1 September 2016

Administered by Department of Health, Disability and Ageing

Legislation au C2014G01386 In force Gazette

Legislation content

COMMONWEALTH OF AUSTRALIA

Department of Health
Therapeutic Goods Administration

THERAPEUTIC GOODS ACT 1989

Section 14 and 14A Notice

 

 

On July 29 2014, the delegate of the Secretary of the Department of Health for the purposes of subsection 14 and 14A of the Therapeutic Goods Act 1989 (“the Act”), by application of AbbVie Pty Ltd, gave consent to:

the importation  and supply, of

 

AUST R No.

Product Name.

76815

levobupivacaine (as hydrochloride)(CHIROCAINE) 25 mg/10 mL injection ampoule

76862

levobupivacaine (as hydrochloride)(CHIROCAINE) 50 mg/10 mL injection ampoule

76864

levobupivacaine (as hydrochloride)(CHIROCAINE) 75 mg/10 mL injection ampoule

94481

levobupivacaine hydrochloride (CHIROCAINE) 125 mg/200 mL solution for injection bag

94482

levobupivacaine hydrochloride (CHIROCAINE) 250 mg/200 mL solution for injection bag

133452

levodopa/carbidopa (DUODOPA) 20 mg/mL and 5 mg/mL intestinal gel PVC bag

29656

isoflurane (FORTHANE) 1 mL/mL inhalation bottle

140509

lopinavir (KALETRA) 100 mg and ritonavir 25 mg tablets bottle

121055

lopinavir (KALETRA) 200 mg and ritonavir 50 mg tablets bottle

78627

KALETRA oral solution bottle

114303

leuprorelin acetate (LUCRIN DEPOT 3 – MONTH) 22.5 mg powder for injection prefilled dual-chamber syringe

114304

leuprorelin acetate (LUCRIN DEPOT 4-MONTH) 30 mg powder for injection prefilled dual-chamber syringe

114302

leuprorelin acetate (LUCRIN DEPOT) 7.5 mg powder for injection prefilled dual-chamber syringe

29658

leuprorelin acetate (LUCRIN) 5 mg/mL injection multidose vial

158301

ritonavir (NORVIR) 100 mg tablet bottle

55004

ritonavir (NORVIR) 600 mg/7.5 mL oral liquid bottle

51919

sevoflurane (SEVORANE) anaesthetic inhalation bottle

121762

paricalcitol (ZEMPLAR) 2 micrograms capsule blister pack

 

that does not conform with the requirements of paragraph 3(2)(l) of the Therapeutic Goods Order No. 69- General requirements for labels for medicines in that the sponsor’s old address (AbbVie Pty Ltd,     32-34 Lord St Botany NSW 2019) is used instead of the sponsor’s new address as of                     September 1, 2014 (AbbVie Pty Ltd, 241 O’Riordan St Mascot NSW 2020) on the labels.

The consent is effective from July 29, 2014 until September 1, 2016 for the products listed in the table above.

The delegate of the Secretary has, under subsection 15(1) of the Act, made the consent subject to the following conditions:

  1. The labels for use are those previously approved bearing the details of the sponsor’s old address.
  2. Details of the process in place to ensure continuous customer contact with your Company as the sponsor are as described in the letter.

 

 

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.